{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T18:53:10Z","timestamp":1785005590848,"version":"3.55.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"46","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Despite near universal health coverage under Medicare, racial disparities persist in the treatment of diffuse large B-cell lymphoma (DLBCL) among older patients in the United States. Studies evaluating DLBCL outcomes often treat socioeconomic status (SES) measures as confounders, potentially introducing biases when SES factors are mediators of disparities in cancer treatment.<\/jats:p>\n            <jats:p>To examine differences in DLBCL treatment, we performed causal mediation analyses of SES measures, including: metropolitan statistical area (MSA) of residence; census-tract poverty level; and private Medicare supplementation using the Surveillance, Epidemiology and End Results-Medicare linked database between 2001 and 2011. In this retrospective cohort study of DLBCL patients ages 66+ years, we conducted a series of multivariable logistic regression analyses estimating odds ratios (OR) and 95% confidence intervals (CI) relating chemo- and\/or immuno-therapy treatment and each SES measure, comparing non-Hispanic (NH)-black, Hispanic\/Latino, and Asian\/Pacific Islander (API) to NH-white patients.<\/jats:p>\n            <jats:p>Compared to NH-white patients, racial\/ethnic minority patients had lower odds of receiving chemo- and\/or immuno-therapy treatment (NH-black: OR 0.84, 95% CI 0.65, 1.08; API: OR 0.80, 95% CI 0.64, 1.01; Hispanic\/Latino: OR 0.78, 95% CI 0.64, 0.96) and higher odds of lacking private Medicare supplementation and residence within an urban MSA and poor census tracts. Adjustment for SES measures as confounders nullified observed racial differences. In causal mediation analyses, between 31% and 38% of race\/ethnicity differences were mediated by having private Medicare supplementation.<\/jats:p>\n            <jats:p>Providing equitable access to Medicare supplementation may reduce disparities in receipt of chemo- and\/or immuno-therapy treatment in older DLBCL patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000017960","type":"journal-article","created":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T13:14:09Z","timestamp":1573737249000},"page":"e17960","source":"Crossref","is-referenced-by-count":11,"title":["Mediation analyses of socioeconomic factors determining racial differences in the treatment of diffuse large B-cell lymphoma in a cohort of older adults"],"prefix":"10.1097","volume":"98","author":[{"given":"Jenny S.","family":"Guadamuz","sequence":"first","affiliation":[{"name":"Department of Pharmacy Systems, Outcomes and Policy, University of Illinois at Chicago"},{"name":"Institute of Minority of Health Research, University of Illinois at Chicago"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine","family":"Ozenberger","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Systems, Outcomes and Policy, University of Illinois at Chicago"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dima M.","family":"Qato","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Systems, Outcomes and Policy, University of Illinois at Chicago"},{"name":"Division of Biostatistics and Epidemiology, University of Illinois at Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi Y.","family":"Ko","sequence":"additional","affiliation":[{"name":"Section of Hematology Oncology, Boston University School of Medicine, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Saffore","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Systems, Outcomes and Policy, University of Illinois at Chicago"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sruthi","family":"Adimadhyam","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Systems, Outcomes and Policy, University of Illinois at Chicago"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley S.","family":"Cha","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Systems, Outcomes and Policy, University of Illinois at Chicago"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kellyn M.","family":"Moran","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Systems, Outcomes and Policy, University of Illinois at Chicago"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Sweiss","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, University of Illinois at Chicago"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pritesh R.","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology, University of Illinois at Chicago"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian C.-H.","family":"Chiu","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, The University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory S.","family":"Calip","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Systems, Outcomes and Policy, University of Illinois at Chicago"},{"name":"Epidemiology Program, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,11]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992\u20132001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1038\/bjc.2015.94","article-title":"Lymphoma incidence,;1; survival and prevalence 2004\u20132014: sub-type analyses from the UK's Haematological Malignancy Research Network","volume":"112","author":"Smith","year":"2015","journal-title":"Br J Cancer"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"R5-20230915","first-page":"5117","article-title":"Survival in advanced diffuse large B-cell lymphoma in pre- and post-rituximab Eras in the United States","volume":"34","author":"Shah","year":"2014","journal-title":"Anticancer Res"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1146\/annurev.med.59.060906.220345","article-title":"A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma","volume":"59","author":"Molina","year":"2008","journal-title":"Annu Rev Med"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1002\/cncr.25765","article-title":"Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States","volume":"117","author":"Shenoy","year":"2011","journal-title":"Cancer"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3109\/10428194.2012.708751","article-title":"Examining racial differences in diffuse large B-cell lymphoma presentation and survival","volume":"54","author":"Flowers","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-2407-10-625","article-title":"Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL)","volume":"10","author":"Griffiths","year":"2010","journal-title":"BMC Cancer"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"4842","DOI":"10.1002\/cncr.27513","article-title":"Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States: report from the National LymphoCare Study","volume":"118","author":"Nabhan","year":"2012","journal-title":"Cancer"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/cncr.28549","article-title":"Insurance status is related to diffuse large B-cell lymphoma survival","volume":"120","author":"Han","year":"2014","journal-title":"Cancer"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1111\/1475-6773.12599","article-title":"Supplemental insurance and racial health disparities under Medicare Part B","volume":"52","author":"Brunt","year":"2016","journal-title":"Health Serv Res"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1001\/jamaoncol.2016.4865","article-title":"Out-of-pocket spending and financial burden among Medicare beneficiaries with cancer","volume":"3","author":"Narang","year":"2017","journal-title":"JAMA Oncol"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/cncr.29808","article-title":"Self-reported financial burden of cancer care and its effect on physical and mental health-related quality of life among US cancer survivors","volume":"122","author":"Kale","year":"2016","journal-title":"Cancer"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1002\/cncr.30560","article-title":"Do cancer survivors change their prescription drug use for financial reasons? Findings from a nationally representative sample in the United States","volume":"123","author":"Zheng","year":"2017","journal-title":"Cancer"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3322\/canjclin.54.2.78","article-title":"Cancer disparities by race\/ethnicity and socioeconomic status","volume":"54","author":"Ward","year":"2004","journal-title":"CA Cancer J Clin"},{"key":"R18-20230915","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1182\/blood-2013-07-517110","article-title":"Socioeconomic disparities in mortality after diffuse large B-cell lymphoma in the modern treatment era","volume":"123","author":"Tao","year":"2014","journal-title":"Blood"},{"key":"R19-20230915","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1002\/cncr.23914","article-title":"Ethnic variations in diagnosis, treatment, socioeconomic status, and survival in a large population-based cohort of elderly patients with non-Hodgkin lymphoma","volume":"113","author":"Wang","year":"2008","journal-title":"Cancer"},{"key":"R20-20230915","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1093\/jnci\/djt211","article-title":"Threats to validity of nonrandomized studies of postdiagnosis exposures on cancer recurrence and survival","volume":"105","author":"Chubak","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"R21-20230915","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10654-009-9331-1","article-title":"Mediation and mechanism","volume":"24","author":"VanderWeele","year":"2009","journal-title":"Eur J Epidemiol"},{"issue":"(8 Suppl)","key":"R22-20230915","article-title":"Utility of the SEER-Medicare data to identify chemotherapy use","volume":"40","author":"Warren","year":"2002","journal-title":"Med Care"},{"key":"R24-20230915","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2147\/CLEP.S105613","article-title":"Use of the Medicare database in epidemiologic and health services research: a valuable source of real-world evidence on the older and disabled populations in the US","volume":"9","author":"Mues","year":"2017","journal-title":"Clin Epidemiol"},{"key":"R25-20230915","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/aje\/kwr146","article-title":"Use of Surveillance, Epidemiology, and End Results-Medicare Data to conduct case-control studies of cancer among the US elderly","volume":"174","author":"Engels","year":"2011","journal-title":"Am J Epidemiol"},{"key":"R27-20230915","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1097\/MLR.0b013e31828fad9f","article-title":"Algorithm for identifying chemotherapy\/biological regimens for metastatic colon cancer in SEER-Medicare","volume":"53","author":"Bikov","year":"2015","journal-title":"Med Care"},{"key":"R28-20230915","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"R32-20230915","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/cncr.23567","article-title":"The impact of socioeconomic status on survival after cancer in the United States","volume":"113","author":"Byers","year":"2008","journal-title":"Cancer"},{"key":"R33-20230915","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/aje\/kww109","article-title":"Does fetal growth restriction cause later obesity? Pitfalls in analyzing causal mediators as confounders","volume":"185","author":"Kramer","year":"2017","journal-title":"Am J Epidemiol"},{"key":"R34-20230915","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood-2014-04-568766","article-title":"Socioeconomic disparities in lymphoma","volume":"123","author":"Flowers","year":"2014","journal-title":"Blood"},{"key":"R35-20230915","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1634\/theoncologist.2014-0386","article-title":"Survival disparities by insurance type for patients aged 15\u201364 years with non-hodgkin lymphoma","volume":"20","author":"Pulte","year":"2015","journal-title":"Oncologist"},{"key":"R36-20230915","first-page":"75","article-title":"Medicare \u2013 35 years of service","volume":"22","author":"De Lew","year":"2000","journal-title":"Health Care Financ Rev"},{"issue":"(Pt 2)","key":"R37-20230915","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1475-6773.2011.01308.x","article-title":"Nonfinancial barriers and access to care for U.S. adults","volume":"47","author":"Kullgren","year":"2012","journal-title":"Health Serv Res"},{"key":"R38-20230915","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/cncr.25542","article-title":"The association of race\/ethnicity, insurance status, and socioeconomic factors with breast cancer care","volume":"117","author":"Freedman","year":"2011","journal-title":"Cancer"},{"issue":"(1 Suppl)","key":"R39-20230915","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1177\/0022146510383498","article-title":"Social conditions as fundamental causes of health inequalities theory, evidence, and policy implications","volume":"51","author":"Phelan","year":"2010","journal-title":"J Health Soc Behav"},{"key":"R40-20230915","doi-asserted-by":"crossref","first-page":"w630","DOI":"10.1377\/hlthaff.26.5.w630","article-title":"Medicare prescription drug benefit progress report: findings from a 2006 national survey of seniors","volume":"26","author":"Neuman","year":"2007","journal-title":"Health Aff"},{"key":"R41-20230915","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1200\/JCO.2014.55.3107","article-title":"Receipt of chemotherapy among Medicare patients with cancer by type of supplemental insurance","volume":"33","author":"Warren","journal-title":"J Clin Oncol"},{"key":"R42-20230915","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1200\/JCO.2015.64.6620","article-title":"Financial insolvency as a risk factor for early mortality among patients with cancer","volume":"34","author":"Ramsey","year":"2016","journal-title":"J Clin Oncol"},{"key":"R43-20230915","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1177\/0193841X9301700202","article-title":"Estimating mediated effects in prevention studies","volume":"17","author":"Mackinnon","year":"1993","journal-title":"Eval Rev"},{"key":"R44-20230915","doi-asserted-by":"crossref","first-page":"879","DOI":"10.3758\/BRM.40.3.879","article-title":"Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models","volume":"40","author":"Preacher","year":"2008","journal-title":"Behav Res Methods"},{"key":"R45-20230915","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1634\/theoncologist.2014-0113","article-title":"Lymphoma treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis","volume":"19","author":"Hamlin","year":"2014","journal-title":"Oncologist"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000017960","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T22:21:58Z","timestamp":1694816518000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000017960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":39,"journal-issue":{"issue":"46","published-online":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000017960","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11]]}}}